December 23, 2009 | 9:18 am
Patrick Bourdet, President and CEO, AREVA Med
We have discussed our efforts in nuclear medicine and the AREVA Med project a couple of times on the blog before, and now I am very pleased tell you about our new website, www.arevamed.com.
Here you will be able to discover more information on the project’s history, basic and technical merit. Through innovation, AREVA Med is determined to develop new powerful anticancer treatments. Please check back often for updates and news as we continue to our efforts in therapies to target cancer.
I hope you are as excited as the AREVA Med team is for this project and what it can bring for oncologists and patients to combat cancer.
President and Chief Executive Officer, AREVA Med
November 10, 2009 | 1:30 pm
by Katherine Berezowskyj
Last week France’s TF1 television network featured AREVA’s innovative work under way in partnership with the U.S. National Cancer Institute and the University of Alabama for the development of a treatment to fight cancer.
The news team got to take a look inside AREVA’s La Hague Facility, in Normandy, where the idea of using AREVA’s expertise in nuclear engineering first came into being. The piece from TF1 also shows the important research and clinical testing underway with partners in the United States.
The clip is a great overview of this project, but unfortunately it’s in French. For those of you who are not fluent, there’s a cheat-sheet with a translation of the video right here (PDF).
AREVA Med, an AREVA subsidiary, is developing innovative methods for the production of the Lead-212 radio-isotope. This isotope has shown to be very promising in tests when used in the targeting therapy called Alpha radio-immunotherapy (Alpha-RIT). Alpha-RIT is a very powerful anti-cancer therapy that works by binding an isotope, like Lead-212, to a monoclonal antibody. Using the body’s own antigens, this treatment targets only cancer cells and destroys them using the high energy of Lead-212. While Alpha-RIT has potential to treat numerous types of cancers, including those that don’t respond well to chemotherapy or radiation, these radio-isotopes have traditionally existed in very limited quantities, hindering the development of new scientific treatments. This is why AREVA has focused on an isotope production method, to make sure Lead-212 is available for cancer research and future treatments.
, AREVA Inc.
, AREVA Med
, AREVA North America
, La Hague
, Nuclear Energy
, Nuclear Medicine
, Nuclear Power
Posted in: Nuclear Energy
, Nuclear Medicine
| No Comments»
September 25, 2009 | 1:44 pm
And if the AREVA Med recognition at the CGI event has you curious for more background on this effort, do see the interview with CEO Patrick Bourdet here:
September 25, 2009 | 10:27 am
N.Y. Times columnist Nicholas Kristof presents the CGI recognition to AREVA Med President Patrick Bourdet…
September 24, 2009 | 2:11 pm
Clinton Global Initiative 2009
Today in New York, the Clinton Global Initiative (CGI) recognized AREVA and its subsidiary AREVA Med LLC for its pioneering work in developing new methods for producing medical-grade Lead 212─ a promising isotope for combating cancer.
As the world leader in clean energy generation, AREVA has rather unique expertise in radiochemistry and nuclear engineering that now we are using to help devise new ways to extract rare isotopes.
AREVA Med President Patrick Bourdet said, “Now that the project has reached important scientific and technical milestones, we are excited to share our optimism about our work. We are committed to the possibility that we can combat cancer with innovative new treatments, and the production of medical-grade lead 212 is a major step forward. We are honored by this recognition by the prestigious Clinton Global Initiative.”
This recognition by the CGI is also an acknowledgement of the work done in cooperation with our remarkable partners, the U.S. National Cancer Institute and the University of Alabama at Birmingham.
Find out more information on AREVA Med LLC here.
And this is the second year in a row that AREVA has been recognized by the CGI. Last year ADAGE, our joint-venture with Duke Energy to build biomass plants, was spotlighted.
May 8, 2009 | 3:48 pm
Announced today, AREVA has formed a new company dedicated to the development of powerful new anti-cancer treatments. AREVA Med LLC will work to target aggressive forms of cancer that currently have limited treatment options. If successful in clinical trails, the new treatments would be used in advanced types of nuclear medicine, such as alpha radio-immunotherapy, for the targeting these aggressive types of cancer. AREVA Med will participate in new treatment development with top oncology centers worldwide. AREVA signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute in Jane 2008 to develop treatment using lead-212. AREVA Inc. President, Jacques Besnainou, said “AREVA Med represents the synthesis of decades of experience in nuclear energy and our company’s long-term commitment to sustainable business approaches, including nuclear materials that could prove beneficial in new applications.”